Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
6th
years
Home>>Products>>cas 388082-78-8 99 Lapatinib ditosylate powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile: +8615207100586

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

cas 388082-78-8 99 Lapatinib ditosylate powder

CAS NO.63968-64-9

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,
Contact Supplier

Product Details

Keywords

  • Artemisinin
  • Artemisinin powder
  • 99% Artemisinin

Quick Details

  • ProName: cas 388082-78-8 99 Lapatinib ditosylat...
  • CasNo: 63968-64-9
  • Molecular Formula: C15H22O5
  • Appearance: white
  • Application: Artemisia annua is used as antimalaria...
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Day
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

cas 388082-78-8 99 Lapatinib ditosylate powder

 Product Name:    Lapatinib ditosylate
CAS:    388082-78-8
MF:    C41H40ClFN4O11S3
MW:    925.46
EINECS:    642-915-3  

 

Details

cas 388082-78-8 99 Lapatinib ditosylate powder

 Product Name:    Lapatinib ditosylate
CAS:    388082-78-8
MF:    C41H40ClFN4O11S3
MW:    925.46
EINECS:    642-915-3  

Lapatinib is available   is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2.  


The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.